Valentina Tateo

Featured in: Favicon

Articles

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer | Journal of Clinical Oncology

Sep 6, 2024 | brnw.ch | Marco Moschini |Antonio Cigliola |Valentina Tateo

Data Sharing StatementData Sharing StatementData SupplementAuthors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials

Dec 11, 2023 | europeanurology.com | Antonio Cigliola |Valentina Tateo |Carlo Bosi |Alberto Briganti

Vale CL, Fisher DJ, Godolphin PJ, et al. Lancet Oncol 2023;24:783–97The meta-analysis by Vale and colleagues reports the effects of docetaxel added to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) according to patient characteristics. The authors proved that docetaxel prolongs overall survival (OS) in patients with poorer prognosis (high-volume [HV] disease and “bulky” T4 stage tumor).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.